Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry.

[1]  C. Tzeng,et al.  Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma , 2017, BMC Infectious Diseases.

[2]  W. Chien,et al.  Prevalence and Mortality-Related Factors of Multiple Myeloma in Taiwan , 2016, PloS one.

[3]  D. Vesole,et al.  Optimal treatment strategies in myeloma: An argument against maintenance therapy after autologous stem cell transplantation. , 2016, Seminars in oncology.

[4]  S. Mailankody,et al.  Controversies in multiple myeloma: Evidence-based update. , 2016, Seminars in oncology.

[5]  Â. Atalla,et al.  Herpes zoster after autologous hematopoietic stem cell transplantation , 2016, Revista brasileira de hematologia e hemoterapia.

[6]  R. Sahoo,et al.  Autologous stem cell transplantation for multiple myeloma: Long-term results. , 2016, The National medical journal of India.

[7]  Michael L. Wang,et al.  Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. , 2016, Journal of the National Cancer Institute.

[8]  C. Tzeng,et al.  Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma , 2015, Medicine.

[9]  P. Moreau,et al.  Frontline therapy of multiple myeloma. , 2015, Blood.

[10]  M. Boccadoro,et al.  Autologous transplantation and maintenance therapy in multiple myeloma. , 2014, The New England journal of medicine.

[11]  B. Cho,et al.  Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma , 2014, Annals of Hematology.

[12]  Wanli Li,et al.  Maintenance Therapy with Immunomodulatory Drugs after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials , 2013, PloS one.

[13]  S. Lonial,et al.  Association of response endpoints with survival outcomes in multiple myeloma , 2013, Leukemia.

[14]  A. Oriol,et al.  Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. , 2012, Blood.

[15]  Baohong Wang,et al.  Novel agents‐based regimens as induction treatment prior to autologous stem‐cell transplantation in newly diagnosed multiple myeloma: a meta‐analysis of randomized controlled trials , 2012, Hematological oncology.

[16]  Claudia Crippa,et al.  Response‐adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression‐free survival in transplanted patients with multiple myeloma , 2012, American journal of hematology.

[17]  M. Dimopoulos,et al.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. , 2011, Blood.

[18]  A. Palumbo,et al.  Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival , 2011, Clinical Cancer Research.

[19]  D. Esseltine,et al.  Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. , 2010, Blood.

[20]  E. Anaissie,et al.  Infections in patients with multiple myeloma. , 2009, Seminars in hematology.

[21]  H. Avet-Loiseau,et al.  The role of complete response in multiple myeloma. , 2009, Blood.

[22]  Yung-Chuan Sung,et al.  Newly diagnosed multiple myeloma in Taiwan , 2009 .

[23]  C. Tzeng,et al.  Haematopoietic stem cell transplantation in Taiwan: past, present, and future. , 2009, Hong Kong medical journal = Xianggang yi xue za zhi.

[24]  J. H. Lee,et al.  Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  P. Hari,et al.  IS THE INTERNATIONAL STAGING SYSTEM SUPERIOR TO THE DURIE SALMON STAGING SYSTEM? A COMPARISON IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANT , 2009, Leukemia.

[26]  C. Tzeng,et al.  Current status of hematopoietic stem cell transplantation in Taiwan , 2008, Bone Marrow Transplantation.

[27]  A. Cheng,et al.  Epidemiology of multiple myeloma in Taiwan , 2007, Cancer.

[28]  J. H. Lee,et al.  New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[30]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[32]  Jia-Hong Chen,et al.  The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation—a single institutional experience in Taiwan , 2014, Annals of Hematology.

[33]  B. Barlogie,et al.  Treatment of multiple myeloma. , 2004, Blood.

[34]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.